Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fecal Microbiota Transplantation for Steroid-Resistant/Dependent Gut Acute GVHD
NCT03214289Phase 1Unknown
- Sponsor
- Sheba Medical Center
- Start
- Jul 2017
- Primary completion
- Jul 2019
- Modality
- Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of fecal microbiome transplant in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Sheba Medical Center. Primary endpoint: Serious adverse events at 28 days. Status: unknown.
02
Drugs
fecal microbiome transplant
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT03214289.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03214289.